Oral Abstract: CML-593 The Novel BCR::ABL1 Allosteric Inhibitor HS-10382/TERN-701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1+ Cancer Cell Lines | Publicación